Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis
Zhenchao Wu, Taikang Yao, Zilu Wang, et al.
British Journal of Cancer (2022) Vol. 128, Iss. 2, pp. 168-176
Open Access | Times Cited: 21

Showing 21 citing articles:

Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension
Hafiz Ahmad, Huma Khan, Shabirul Haque, et al.
Journal of the Renin-Angiotensin-Aldosterone System (2023) Vol. 2023
Open Access | Times Cited: 40
ACE-Inhibitors in Hypertension: A Historical Perspective and Current Insights
Stacey Cutrell, Ibrahim S. Alhomoud, Anurag Mehta, et al.
Current Hypertension Reports (2023) Vol. 25, Iss. 9, pp. 243-250
Closed Access | Times Cited: 31
Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases
Lívia da Cunha Agostini, Nayara Nascimento Toledo Silva, Vanessa A. Belo, et al.
European Journal of Pharmacology (2024) Vol. 981, pp. 176907-176907
Closed Access | Times Cited: 5
Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian randomization analysis
Zehui Yao, Dailei Qin, Jianzhong Cao, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives
Shahzeb Imran, Medha Sridhar Rao, Muhammad Hamza Shah, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 3, pp. 102389-102389
Open Access | Times Cited: 4
Beyond blood pressure, fluid and electrolyte homeostasis – Role of the renin angiotensin aldosterone system in the interplay between metabolic diseases and breast cancer
Nishan S. Kalupahana, Naïma Moustaïd‐Moussa
Acta Physiologica (2024) Vol. 240, Iss. 7
Closed Access | Times Cited: 3
Association Between ACE2 and Lung Diseases
Cheng Su, Li Cai, Xinyi Hu, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 1771-1780
Open Access | Times Cited: 2
Advanced progress of the relationship between renin–angiotensin–aldosterone system inhibitors and cancers
Ruixing Zhang, Hongtao Yin, Mengdi Yang, et al.
Journal of Hypertension (2024) Vol. 42, Iss. 11, pp. 1862-1873
Closed Access | Times Cited: 1
Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review
J Pawlonka, Barbara Buchalska, Kasper Buczma, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 11, pp. 1406-1427
Open Access | Times Cited: 1
Association between angiotensin-converting enzyme inhibitor-induced cough and the risk of lung cancer: a Mendelian randomization study
Taikang Yao, Zhenchao Wu, Zilu Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
An angiotensin system inhibitor (losartan) potentiates antitumor efficacy of cisplatin in a murine model of non–small cell lung cancer
Hexiao Tang, Eric Abston, Mozhdeh Sojoodi, et al.
JTCVS Open (2024) Vol. 18, pp. 306-321
Open Access | Times Cited: 1
Classical and non-classical effects of angiotensin converting enzyme: how increased ACE enhances myeloid immune function.
Kenneth E. Bernstein, Duo‐Yao Cao, Tomohiro Shibata, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 6, pp. 107388-107388
Open Access | Times Cited: 1
Chronic mitochondrial dynamic-targeted therapy alleviates left ventricular dysfunction by reducing multiple programmed cell death in post-myocardial infarction rats
Chanon Piamsiri, Chayodom Maneechote, Kewarin Jinawong, et al.
European Journal of Pharmacology (2024) Vol. 977, pp. 176736-176736
Closed Access | Times Cited: 1
Long-term Use of Angiotensin-converting Enzyme Inhibitors Increases Substance P Levels, Which is Involved in the Risk of Lung Cancer
Miguel Muñoz, Antonio Pavón
Archivos de Bronconeumología (2023) Vol. 59, Iss. 12, pp. 848-849
Open Access | Times Cited: 2
ACE inhibitors and lung cancer: There is more to it than just a cough
Muhammad Ahmad, Malik Waleed Zeb Khan, Shandana Ali, et al.
European Journal of Internal Medicine (2024) Vol. 123, pp. 159-160
Closed Access
Is meta-analysis the "top of the evidence pyramid" in cardiology?
S. Yu. Martsevich
CARDIOVASCULAR THERAPY AND PREVENTION (2024) Vol. 23, Iss. 1, pp. 3925-3925
Open Access
Causal linkage between angiotensin-converting enzyme 2 and risk of lung cancer: a bidirectional two-sample Mendelian randomization study
Shubin Chen, Ruiling Ning, Wei Jiang, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
Role of ACE Inhibitors in Transforming Renin–Angiotensin System
Mukesh Nandave
(2024), pp. 153-221
Closed Access
Substance P in cancer
Miguel Muñoz, Marisa Rosso, Riffat Mehboob, et al.
Elsevier eBooks (2024), pp. 373-399
Closed Access
Effects of ACE inhibitors/ARBs on lung cancer; an updated mini-review on recent data
Zahra Golestani Hotkani, Tella Sadighpour, Ali Shirbacheh, et al.
Journal of Renal Endocrinology (2024) Vol. 10, pp. e25175-e25175
Closed Access
ACE inhibitors and the risk of lung cancer—is there causality?
Martin H. Strauss, İlke Sipahi, Alistair S. Hall
British Journal of Cancer (2023) Vol. 129, Iss. 4, pp. 570-571
Open Access
ACE-Hemmer und Lungenkrebsrisiko - eine kontroverse Debatte
Daniel Hamberger
InFo Hämatologie + Onkologie (2023) Vol. 26, Iss. 7-8, pp. 29-30
Closed Access
Page 1

Scroll to top